Clinical Trials List
Protocol Number20180101
2021-04-01 - 2022-12-20
Phase I
Recruiting2
ICD-10C61
Malignant neoplasm of prostate
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9185
Malignant neoplasm of prostate
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 黃文冠 Division of Hematology & Oncology
- Kai-Jie Yu Division of Hematology & Oncology
- 黃亮鋼 Division of Hematology & Oncology
- 沈鼎文 Division of Radiology
- Po-Jung Su Division of Hematology & Oncology
- See-Tong Pang Division of Hematology & Oncology
- Yuan-Cheng Chu Division of Hematology & Oncology
- Feng-Yuan Liu Division of Nuclear Medicine
- 張境夫 Division of Hematology & Oncology
- 林柏宏 Division of Hematology & Oncology
- I-hung Shao Division of Hematology & Oncology
- PO-HUNG LIN Division of Hematology & Oncology
- Ming-Mo Hou Division of Hematology & Oncology
- Rita cheng Division of Hematology & Oncology
- Hong-Cheng Gan Division of Hematology & Oncology
- Jing-Ren Tseng Division of Nuclear Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- - - Division of Urology
- Yu-Chieh Tsai Division of Hematology & Oncology
- KO-JEN LI Division of General Internal Medicine
- 劉詩彬 Division of Urology
- JIAN-HUA HONG Division of Urology
- FU-JEN HSUEH Division of Hematology & Oncology
- CHUNG-HSIN CHEN Division of Urology
- Ying-Chun Shen Division of Hematology & Oncology
- YEN-HENG LIN Division of Radiology
- YU-CHUAN LU Division of Urology
- JHE-CYUAN GUO Division of Hematology & Oncology
- CHING-CHU LU Division of Nuclear Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
10 participants
-
Global
288 participants
